What is the evidence that personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve outcomes?

Name: What is the evidence that personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient's disease are aligned with specific therapy, will improve outcomes?
Uploaded: 2016-07-25T00:00:00+00:00
Description: What is the evidence that more personalized, gene-directed cancer therapy, in which specific molecular drivers of a patient’s disease are aligned with specific therapy, will improve patient outcomes? To what extent are they improved with targeted therapy, in breast, lung (NSLC), and colorectal cancer?

CLICK HERE FOR CME CREDIT

Created by

Presenter

Professor Lynn Wang, MD, PhD, FCAP

Professor, Division of Genomic and Molecular Pathology
Founding Medical Director
Genomic and Molecular Pathology
University of Chicago Medical Center
Chicago, IL, USA

Related Videos

Video

What is FoundationOne Heme? How accurate are its detection rates and how is it used to detect genomic alterations that can impact diagnosis, therapy and prognosis in hematologic cancers?

What is FoundationOne Heme? How accurate are its detection rates and how is it being used to detect genomic alterations that can impact diagnosis, therapy selection and prognosis in hematologic cancers?

Video

What categories of genomic alterations are identified by the method of genomic profiling you are familiar with? Are any critical genomic alterations not identified by NGS?

What categories of genomic alterations are identified by the method of genomic profiling you are familiar with? Do they include all classes of alterations, i.e. base substitutions, insertions/deletions, copy number alterations and rearrangements? ...

Video

What kind of clinical samples are required to implement next generation sequencing (NGS)? Can NGS be applied to samples other than FFPE?

Video

What does it mean that a tumor sample has a mutation or rearrangement? Exactly what is being measured? Is the presence of a mutation on an NGS panel an "all-or-none" phenomenon?

Exactly what does it mean that a tumor sample has a mutation or rearrangement? Exactly what is being measured? Is the presence of a mutation on an NGS panel an “all-or–none” phenomenon or are there additional quantitative levels of characterization ...